Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-α production by mast cells

Journal of Immunology

Volumn 156, Issue 1, 1996, Pages 218-223

  Bissonnette, Elyse Y ^a   Enciso, J Antonio ^b   Befus, A Dean ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HOSPITAL DE PEDIATRÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; DRUG METABOLITE; HISTAMINE; MESALAZINE; MESSENGER RNA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HISTAMINE RELEASE; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; INTESTINE MUCOSA; MALE; NONHUMAN; PERITONEUM MAST CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT;

ANIMALS; ASCITIC FLUID; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HISTAMINE RELEASE; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; MAST CELLS; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030028383     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Riley, S. A . and L. A Turnberg. 1990 Sulfasalazine and the aminosalicylates in the treatment of inflammatory bowel disease Q. J. Med. 75.551
2. Bax, D. E., M. S. Greaves, and R. S. Amos. 1986. Sulfasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype, and response to treatment. Br. J. Rheumatol 25:282
3. Azad Khan, A. K., G. Guthrie, H H. Johnston, S. C Truelove, and D. H. Williamson. 1983. Tissue and bacterial splitting of sulfasalazine. Clin Sci. 64:349
4. Van Hees, P , J. Bakker, and J. Van Toneren 1980. Effect of sulfasalazine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis a study to determine the active therapeutic moiety of sulfasalazine Gut 21:632.
5. Neumann, V., A. Taggart, P. LeGallez, C. Astbury, J Hill, and H A. Bird. 1986. A study to determine the active moiety of sulfasalazine in rheumatoid arthritis J. Rheumatol. 13:285.
6. MacDermott, R. P., S. R Schloemann, M. J Bertovich, G. S Nash, M. Peters, and W. F. Stenson. 1989. Inhibition of antibody secretion by 5-aminosalicylic acid Gastroenterology 96:442
7. Williams, J. G., and M. B. Hallett. 1989. Effect of sulfasalazine and its active metabolite, 5-aminosalicylic acid, on toxic oxygen metabolite production by neutrophils. Gut 30:1581.
8. Shanahan, F., A. Niederlehner, R P MacDermott, W. F. Stenson, M G Kane, and S. Targan. 1986 Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes Immunopharmacology 11:111.
9. Aparicio-Pagés, M N., H W. Verspaget, J C. M Hafkenscheid, G. E. Crama-Bohbouth, A S Pen̄a, I. T Weterman, and C B. H. W. Lamers 1990. Inhibition of cell-mediated cytotoxicity by sulfasalazine, effect of in vivo treatment with 5-aminosalicylic acid and sulfasalazine on in vitro natural killer cell activity. Gut 31.1030.
10. Tornhamre, S., C Edenius, G. Smedegård, B. Sjoquist, and J Å. Lindgren. 1989. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products. Eur. J. Pharmacol. 169:225.
11. Eliakim, R., F. Karmeli, E Razin, and D. Rachmilewitz. 1988. Role of platelet-activating factor in ulcerative colitis Gastroenterology 95:1167.
12. Balazs, M., G. Illyes, and G Vadasz. 1989. Mast cells in ulcerative colitis Quantitative and ultrastructural studies Virchows Arch. B. Cell Pathol. 57:353.
13. Crisp, A J., C. M. Chapman, S. E. Kirkham, A L. Schiller, and S. M. Krane 1984 Articular mastocytosis in rheumatoid arthritis Arthritis Rheum 27:845.
14. Strobel, S., A Busuttil, and A Ferguson 1983. Human intestinal mucosal mast cells expanded population in untreated coeliac disease. Gut 24 222.
15. Fiocchi, C. 1992. Cytokines. In Inflammatory Bowel Disease. R. P. MacDermott and W F. Stenson, eds. Elsevier, New York, p 137.
16. Befus, A. D. 1994 Inflammation: mast cells. In Mucosal Immunology. Cells. Regulation, and Specificity in the Mucosal Immune System: Effector Sites. P L Ogra, J Mestecky, M. Lamm, W. Strober, J McGhee, and J. Bienenstock, eds. Academic Press, Inc., Orlando, FL, p 307
17. Benyon, R. C., M. A. Lowman, P H. Rees, S T. Holgate, and M. K Church. 1989. Mast cell heterogeneity. In Asthma Reviews, Vol. 2. J Morley. ed Academic Press, Inc., London, p. 151.
18. Holgate, S. T. 1988 Mast Cells, Mediators, and Disease Kluwer, Boston, p 289.
19. Bissonnette, E Y , R C. Benyon, and A. D. Befus. 1990 Mast cells as targets for the therapy of inflammatory bowel disease Can J. Gastroenterol. 4:285.
20. Barrett, K E , T. L. Tashof, and D D. Metcalfe. 1985. Inhibition of IgE mediated mast cell degranulation by sulfasalazine. Eur. J. Pharmacol. 107:279
21. Gordon, J. R., and S. J Galli. 1990. Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin Nature 346:274.
22. Bissonnette, E. Y., and A. D. Befus. 1990. Inhibition of mast cell-mediated cytotoxicity by IFN-α/β and -γ. J. Immunol. 145:3385.
23. Strieter, R. M., S. L. Kunkel, and R. C. Bone. 1993. Role of tumor necrosis factor-γ in disease states and inflammation. Crit. Care Med. 21.S447.
24. Larrick, J. W , and S C. Wright 1990. Cytotoxic mechanism of tumor necrosis factor-α. FASEB J. 4:3215.
25. Rosenblum, M G , and N. J Donato. 1989. Tumor necrosis factor-α: a multi-faceted peptide hormone. Crit Rev Immunol. 9:21
26. Shanahan, F., A. Niederlehner, N. Carramanzana, and P. Anton. 1990. Sulfasalazine inhibits the binding of TNF-α to its receptor Immunopharmacology 20.217.
27. Lee, T. D. G., F Shanahan, H. R. P Miller, J Bienenstock, and A. D Befus 1985. Intestinal mucosal mast cells: isolation from rat lamina propria and purification using unit gravity velocity sedimentation Immunology 55:721.
28. Bissonnette, E. Y , B. Chin, and A. D. Befus. 1995. Isolation and characterization of intestinal mucosal mast cells. In Methods of Gastrointestinal Pharmacology (A Handbook). T S. Gaginella, ed CRC Press, New York. p. 405.
29. Bissonnette, E Y., B. Chin, and A. D Befus Interferons differentially regulate histamine and TNF-α in rat intestinal mucosal mast cells. Immunology 86:12.
30. Shore, P. A., A Burkhalter, and V. H. Cohn, Jr. 1959. A method for the fluorometric assay of histamine in tissues J Pharmacol Exp. Ther. 127:182
31. Pross, H F., M G Baines, P. Rubin, P. Shragge, and M. S. Palterson. 1981. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantification of natural killer activity J. Clin. Immunol. 1:51.
32. 3H]thymidine incorporation assay. J. Immunol Methods 170: 211
33. Sette, A., L Adorni, E. Mambini, and G. Doria. 1986. A microcomputer program for probit analysis of interleukin-2 titration data J. Immunol. Methods 86:265.
34. Chomczynski. P . and N. Sacchi 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal. Biochem. 162: 156.
35. Sambrook, J , E F Fritsch, and T. Maniatis 1989. Molecular cloning A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
36. Pennica, D , J. S. Hayflick, T S. Bringman, M A Palladino, and D V Goeddel. 1985. Cloning and expression in Escherichia coli of the cDNA for murine tumour necrosis factor Proc. Natl. Acad Sci. USA 82:6060.
37. Bottiger, L. E 1958 A simple clinical method for the determination of salazopyrin (azulfidine) in serum Scand. J. Clin Lab. Invest 10.108
38. Hernandez-Asensio, M., J J. Hooks, S. Ida, R. P. Siraganian, and A. L. Notkins. 1979. Interferon-induced enhancement of IgE-mediated histamine release from human basophils requires RNA synthesis. J. Immunol 122:1601.
39. Ireland, A., and D. P. Jewell. 1990. Mechanism of action of 5-aminosalicylic acid and its derivatives. Clin. Sci. 78:119.
40. Hogaboam, C M , D. Donigi-Gale, T. S Shoupe, E. Y. Bissonnette, A. D. Befus, and J. L Wallace 1992. Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds. Br. J Pharmacol. 105:87.
41. SaKemini, D. E., E. Masini, E. Anggard, P F Mannaioni, and J. Vane. 1990. Synthesis of a nitric oxide-like factor from L-arginine by rat serosal mast cells: stimulation of guanylate cyclase and inhibition of platelet aggregation Biochem. Biophys. Res Commun 169:696.
42. Bissonnette, E Y., C. M. Hogaboam, J. L Wallace, and A. D. Befus 1991. Potentiation of tumor necrosis factor-α-mediated cytotoxicity of mast cells by their production of nitric oxide. J. Immunol. 147:3060.
43. Fox, C. C., W C. Moore, and L. M. Lichtenstein 1990. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig. Dis. Sci. 36:179.
44. Gagmella, T S., and R. E. Walsh 1992 Sulfasalazme Multiplicity of action Dig Dis. Sci 37:801.
45. Allgayer, H , and W. F. Stenson 1988 A comparison of effects of sulfasalazine and its metabolites on the metabolism of endogenous versus exogenous arachidonic acid Immunopharmacology 15:39
46. 2 from activated mast cells and its possible involvement m the regulation of the degranulation process Eur. J. Biochem 209:257.
47. Garg, G. P., C H. Cho, and C W. Ogle. 1990 Inhibition of stress-induced gastric ulcers by sulfasalazine and its constituents (sulfapyridine and 5-aminosalicylic acid) in rats Pharmacology 40:318.
48. Fox, C C., W. C. Moore, and L. M Lichtenstein 1990 Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig. Dis. Sci. 36:179.